(Q35177567)

6 August 2017

1 reference

title

Combinatorial immunotherapies for infectious diseases (English)

1 reference

6 August 2017

1 reference

1

Hartmut Hengel

1 reference

6 August 2017

K Noel Masihi

2

1 reference

6 August 2017

publication date

1 August 2003

1 reference

International Immunopharmacology

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

8

1 reference

6 August 2017

page(s)

1159-1167

1 reference

Fighting infection using immunomodulatory agents

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Immunomodulators in infectious diseases: panoply of possibilites

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Development of immunotherapeutic strategies for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Immunomodulators as adjunctive therapy for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Current and future therapies of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Immunotherapy of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Filgrastim in patients with pneumonia and severe sepsis or septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Antibacterial agents--phagocytes: new concepts for old in immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Immunomodulating activity of quinolones: review.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Passive immunity in prevention and treatment of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Hyperimmune globulin prophylaxis for cytomegalovirus infection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Adjunctive immune therapy for fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Combination immunotherapy and antifungal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Host Immune Reactivity Determines the Efficacy of Combination Immunotherapy and Antifungal Chemotherapy in Candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Synergism of IL-2-stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Low interleukin-12 activity in severe Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Hijacking and exploitation of IL-10 by intracellular pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900028-6

7 January 2021

10.1016/S1567-5769(03)00028-6

Identifiers

DOI

1 reference

6 August 2017

1 reference